Raymond James Financial
BPMC

Raymond James Financial’s Blueprint Medicines BPMC Stock Holding History

Raymond James Financial’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-66,461
Closed -$8.52M – 5197
2025
Q2 		$8.52M Sell
66,461
-127,351
-66% -$13.2M ﹤0.01% 1997
2025
Q1 		$17.2M Sell
193,812
-48,154
-20% -$4.7M 0.01% 1425
2024
Q4 		$21.1M Buy
+241,966
New +$22.2M 0.01% 1269

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Raymond James Financial's BPMC Position: Q3 2025 in Review

Raymond James Financial sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 66,461 shares — an estimated $8.52M sold.

Raymond James Financial first reported a position in BPMC in Q4 2024 and held it in 3 quarters. The position peaked at $21.1M in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Raymond James Financial reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 66,461 Blueprint Medicines shares in Q3 2025, an estimated $8.52M.
  • Raymond James Financial first reported a position in Blueprint Medicines in Q4 2024 and held it in 3 quarters.
  • Raymond James Financial's Blueprint Medicines position peaked at $21.1M in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.